Ubs Group Ag Synthetic Biologics, Inc. Transaction History

Ubs Group Ag

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$1.9 - $2.9 $143,947 - $219,709	-75,762 Reduced 94.88%	4,089 $1,000
Q1 2022 May 16, 2022	SELL	$2.3 - $4.3 $40,312 - $75,366	-17,527 Reduced 18.0%	79,851 $23,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.5 $121,140 - $201,901	44,867 Added 85.44%	97,378 $26,000
Q3 2021 Nov 15, 2021	BUY	$4.3 - $5.8 $225,543 - $304,221	52,452 Added 88901.69%	52,511 $24,000
Q2 2021 Aug 13, 2021	SELL	$4.6 - $7.2 $2.65 Million - $4.15 Million	-576,868 Reduced 99.99%	59 $0
Q1 2021 May 12, 2021	BUY	$5.0 - $11.7 $2.88 Million - $6.75 Million	576,927 New	576,927 $393,000
Q4 2020 Feb 11, 2021	SELL	$2.9 - $4.6 $249 - $395	-86 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$4.5 - $7.1 $112,765 - $177,918	-25,059 Reduced 99.66%	86 $0
Q2 2020 Jul 31, 2020	SELL	$2.8 - $5.7 $229,815 - $467,838	-82,077 Reduced 76.55%	25,145 $13,000
Q1 2020 May 01, 2020	BUY	$2.7 - $6.1 $288,495 - $651,785	106,850 Added 28723.12%	107,222 $34,000
Q4 2019 Feb 14, 2020	SELL	$3.9 - $5.3 $105,514 - $143,391	-27,055 Reduced 98.64%	372 $0
Q3 2019 Nov 14, 2019	BUY	$3.9 - $5.9 $104,625 - $158,279	26,827 Added 4471.17%	27,427 $12,000
Q2 2019 Aug 14, 2019	SELL	$4.9 - $6.6 $16,552 - $22,294	-3,378 Reduced 84.92%	600 $0
Q1 2019 May 14, 2019	SELL	$5.9 - $8.1 $115,982 - $159,229	-19,658 Reduced 83.17%	3,978 $2,000
Q4 2018 Feb 14, 2019	BUY	$5.2 - $26.8 $118,950 - $613,050	22,875 Added 3005.91%	23,636 $13,000
Q3 2018 Nov 14, 2018	BUY	$20.4 - $80.5 $15,524 - $61,260	761 New	761 $2,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.